Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Jitendra Vasandani MD PA

Neither a doctor nor a teaching hospital

Research payments

$3,315,677

545 payments

Through program year 2025, Jitendra Vasandani MD PA is reported as receiving $3,315,677 in research payments, across 545 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $527,496 46
2024 Research $622,419 54
2023 Research $379,584 42
2022 Research $974,030 253
2021 Research $439,323 75
2020 Research $302,643 58
2019 Research $70,183 17

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sun Pharmaceutical Industries Inc. $1,980,067 191 payments
  2. GlaxoSmithKline, LLC. $884,875 266 payments
  3. AbbVie, Inc. $168,101 42 payments
  4. Janssen Research & Development, LLC $159,115 27 payments
  5. Ucb SA $77,383 3 payments
  6. Regeneron Pharmaceuticals, Inc. $39,637 15 payments
  7. Gilead Sciences, Inc. $6,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $869,293 104 payments
  2. Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) $670,192 44 payments
  3. A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $480,686 130 payments
  4. A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $337,393 109 payments
  5. INSPIRE LTE study $270,971 30 payments
  6. A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease $103,229 13 payments
  7. A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) $98,296 29 payments
  8. Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $96,693 6 payments
  9. A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. $77,383 3 payments
  10. Efficacy and Safety of ILUMYA Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) $72,917 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record